Akm Khairuzzaman

Akm Khairuzzaman is a Branch Chief at FDA’s Office of Office of Pharmaceutical Quality, CDER, where he leads a group of review scientist responsible for assessment of chemistry, manufacturing, controls (CMC) for investigational new drug applications (IND), new drug application (NDA), and abbreviated new drug application (ANDA) seeking approval in US market.